Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 172

1.

Rifaximin alters gut microbiota profile, but does not affect systemic inflammation - a randomized controlled trial in common variable immunodeficiency.

Jørgensen SF, Macpherson ME, Bjørnetrø T, Holm K, Kummen M, Rashidi A, Michelsen AE, Lekva T, Halvorsen B, Trøseid M, Mollnes TE, Berge RK, Yndestad A, Ueland T, Karlsen TH, Aukrust P, Hov JR, Fevang B.

Sci Rep. 2019 Jan 17;9(1):167. doi: 10.1038/s41598-018-35367-7.

2.

GPR35 promotes glycolysis, proliferation, and oncogenic signaling by engaging with the sodium potassium pump.

Schneditz G, Elias JE, Pagano E, Zaeem Cader M, Saveljeva S, Long K, Mukhopadhyay S, Arasteh M, Lawley TD, Dougan G, Bassett A, Karlsen TH, Kaser A, Kaneider NC.

Sci Signal. 2019 Jan 1;12(562). pii: eaau9048. doi: 10.1126/scisignal.aau9048.

PMID:
30600262
3.

The EASL International Liver Foundation: A growing pup with missions that are distinct yet integrated with those of its mother.

Colombo M, Karlsen TH.

J Hepatol. 2018 Dec 18. pii: S0168-8278(18)32568-6. doi: 10.1016/j.jhep.2018.11.017. [Epub ahead of print] No abstract available.

PMID:
30577976
4.

Factors Associated With Outcomes of Patients With Primary Sclerosing Cholangitis and Development and Validation of a Risk Scoring System.

Goode EC, Clark AB, Mells GM, Srivastava B, Spiess K, Gelson WTH, Trivedi PJ, Lynch KD, Castren E, Vesterhus MN, Karlsen TH, Ji SG, Anderson CA, Thorburn D, Hudson M, M H, Aldersley MA, Bathgate A, Sandford RN, Alexander GJ, Chapman RW, Walmsley M; UK-PSC Consortium, Hirschfield GM, Rushbrook SM.

Hepatology. 2018 Dec 19. doi: 10.1002/hep.30479. [Epub ahead of print]

PMID:
30566748
5.

Clinical Practice Guidelines of the European Association for the study of the Liver - Advancing methodology but preserving practicability.

Cornberg M, Tacke F, Karlsen TH; European Association for the Study of the Liver.

J Hepatol. 2019 Jan;70(1):5-7. doi: 10.1016/j.jhep.2018.10.011. Epub 2018 Nov 9. No abstract available.

PMID:
30420159
6.

Genetic and transcriptional analysis of inflammatory bowel disease-associated pathways in patients with GUCY2C-linked familial diarrhea.

Tronstad RR, Polushina T, Brattbakk HR, Stansberg C, von Volkmann HL, Hanevik K, Ellinghaus E, Jørgensen SF, Ersland KM, Pham KD, Gilja OH, Hovdenak N, Hausken T, Vatn MH, Franke A, Knappskog PM, Le Hellard S, Karlsen TH, Fiskerstrand T.

Scand J Gastroenterol. 2018 Oct - Nov;53(10-11):1264-1273. doi: 10.1080/00365521.2018.1521867. Epub 2018 Oct 24.

PMID:
30353760
7.

Circulating markers of gut barrier function associated with disease severity in primary sclerosing cholangitis.

Dhillon AK, Kummen M, Trøseid M, Åkra S, Liaskou E, Moum B, Vesterhus M, Karlsen TH, Seljeflot I, Hov JR.

Liver Int. 2019 Feb;39(2):371-381. doi: 10.1111/liv.13979. Epub 2018 Oct 24.

PMID:
30269440
8.

Cancer After Liver Transplantation in Children and Young Adults: A Population-Based Study From 4 Nordic Countries.

Åberg F, Isoniemi H, Pukkala E, Jalanko H, Rasmussen A, Storm HH, Schultz N, Bennet W, Ekvall N, Ericzon BG, Malenicka S, Tretli S, Line PD, Boberg KM, Østensen A, Karlsen TH, Nordin A.

Liver Transpl. 2018 Sep;24(9):1252-1259. doi: 10.1002/lt.25305.

PMID:
30120902
9.

Natural killer T cells mediate inflammation in the bile ducts.

Berntsen NL, Fosby B, Tan C, Reims HM, Ogaard J, Jiang X, Schrumpf E, Valestrand L, Karlsen TH, Line PD, Blumberg RS, Melum E.

Mucosal Immunol. 2018 Nov;11(6):1582-1590. doi: 10.1038/s41385-018-0066-8. Epub 2018 Aug 16.

PMID:
30115993
10.

Neoplastic Transformation of the Peribiliary Stem Cell Niche in Cholangiocarcinoma Arisen in Primary Sclerosing Cholangitis.

Carpino G, Cardinale V, Folseraas T, Overi D, Grzyb K, Costantini D, Berloco PB, Di Matteo S, Karlsen TH, Alvaro D, Gaudio E.

Hepatology. 2019 Feb;69(2):622-638. doi: 10.1002/hep.30210. Epub 2019 Jan 4.

PMID:
30102768
11.

Gut and Liver B Cells of Common Clonal Origin in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease.

Chung BK, Henriksen EKK, Jørgensen KK, Karlsen TH, Hirschfield GM, Liaskou E.

Hepatol Commun. 2018 Aug 6;2(8):956-967. doi: 10.1002/hep4.1200. eCollection 2018 Aug.

12.

The Lancet-EASL Commission on liver diseases in Europe: overcoming unmet needs, stigma, and inequities.

Manns MP, Burra P, Sargent J, Horton R, Karlsen TH.

Lancet. 2018 Aug 25;392(10148):621-622. doi: 10.1016/S0140-6736(18)31734-3. Epub 2018 Jul 27. No abstract available.

PMID:
30060999
13.

Serological markers of extracellular matrix remodeling predict transplant-free survival in primary sclerosing cholangitis.

Nielsen MJ, Thorburn D, Leeming DJ, Hov JR, Nygård S, Moum B, Saffioti F, Gilja OH, Boberg KM, Mazza G, Røsjø H, Pinzani M, Karlsen TH, Karsdal MA, Vesterhus M.

Aliment Pharmacol Ther. 2018 Jul;48(2):179-189. doi: 10.1111/apt.14806. Epub 2018 May 30.

PMID:
29851098
14.

Primary Sclerosing Cholangitis Risk Estimate Tool (PREsTo) Predicts Outcomes of the Disease: A Derivation and Validation Study Using Machine Learning.

Eaton JE, Vesterhus M, McCauley BM, Atkinson EJ, Schlicht EM, Juran BD, Gossard AA, LaRusso NF, Gores GJ, Karlsen TH, Lazaridis KN.

Hepatology. 2018 May 9. doi: 10.1002/hep.30085. [Epub ahead of print]

PMID:
29742811
15.

Lysyl oxidase-like protein 2 (LOXL2) modulates barrier function in cholangiocytes in cholestasis.

Pollheimer MJ, Racedo S, Mikels-Vigdal A, Marshall D, Bowlus C, Lackner C, Madl T, Karlsen TH, Hov JR, Lyman SK, Adamkewicz J, Smith V, Moreau E, Zollner G, Eide TJ, Stojakovic T, Scharnagl H, Gruber HJ, Stauber RE, Trauner M, Fickert P.

J Hepatol. 2018 Aug;69(2):368-377. doi: 10.1016/j.jhep.2018.04.009. Epub 2018 Apr 28.

PMID:
29709678
16.

«The times they are a'changin'» - Positioning the European Association for the Study of the Liver in the changing landscape of hepatology.

Karlsen TH, Tacke F.

J Hepatol. 2018 May;68(5):873-875. doi: 10.1016/j.jhep.2018.02.001. Epub 2018 Mar 2. No abstract available.

PMID:
29500035
17.

Correction: Immune-related genetic enrichment in frontotemporal dementia: An analysis of genome-wide association studies.

Broce I, Karch CM, Wen N, Fan CC, Wang Y, Tan CH, Kouri N, Ross OA, Höglinger GU, Muller U, Hardy J; International FTD-Genomics Consortium, Momeni P, Hess CP, Dillon WP, Miller ZA, Bonham LW, Rabinovici GD, Rosen HJ, Schellenberg GD, Franke A, Karlsen TH, Veldink JH, Ferrari R, Yokoyama JS, Miller BL, Andreassen OA, Dale AM, Desikan RS, Sugrue LP.

PLoS Med. 2018 Jan 29;15(1):e1002504. doi: 10.1371/journal.pmed.1002504. eCollection 2018 Jan.

18.

Immune-related genetic enrichment in frontotemporal dementia: An analysis of genome-wide association studies.

Broce I, Karch CM, Wen N, Fan CC, Wang Y, Tan CH, Kouri N, Ross OA, Höglinger GU, Muller U, Hardy J; International FTD-Genomics Consortium, Momeni P, Hess CP, Dillon WP, Miller ZA, Bonham LW, Rabinovici GD, Rosen HJ, Schellenberg GD, Franke A, Karlsen TH, Veldink JH, Ferrari R, Yokoyama JS, Miller BL, Andreassen OA, Dale AM, Desikan RS, Sugrue LP.

PLoS Med. 2018 Jan 9;15(1):e1002487. doi: 10.1371/journal.pmed.1002487. eCollection 2018 Jan. Erratum in: PLoS Med. 2018 Jan 29;15(1):e1002504.

19.

The Microbiome in Primary Sclerosing Cholangitis: Current Evidence and Potential Concepts.

Hov JR, Karlsen TH.

Semin Liver Dis. 2017 Nov;37(4):314-331. doi: 10.1055/s-0037-1608801. Epub 2017 Dec 22. Review.

PMID:
29272894
20.

Hepatic Stem/Progenitor Cell Activation Differs between Primary Sclerosing and Primary Biliary Cholangitis.

Carpino G, Cardinale V, Folseraas T, Overi D, Floreani A, Franchitto A, Onori P, Cazzagon N, Berloco PB, Karlsen TH, Alvaro D, Gaudio E.

Am J Pathol. 2018 Mar;188(3):627-639. doi: 10.1016/j.ajpath.2017.11.010. Epub 2017 Dec 15.

PMID:
29248458

Supplemental Content

Loading ...
Support Center